A new trading day began on Friday, with CRISPR Therapeutics AG (NASDAQ: CRSP) stock price down -2.22% from the previous day of trading, before settling in for the closing price of $40.61. CRSP’s price has ranged from $36.52 to $91.10 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 39460.20% over the past five years. Meanwhile, its annual earnings per share averaged -166.03%. With a float of $81.60 million, this company’s outstanding shares have now reached $85.34 million.
Let’s look at the performance matrix of the company that is accounted for 407 employees. In terms of profitability, gross margin is 30.6%, operating margin of -164.86%, and the pretax margin is -117.29%.
CRISPR Therapeutics AG (CRSP) Insider and Institutional Ownership
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of CRISPR Therapeutics AG is 4.30%, while institutional ownership is 68.73%. The most recent insider transaction that took place on Dec 02 ’24, was worth 826,564. In this transaction Chief Executive Officer of this company sold 15,000 shares at a rate of $55.10, taking the stock ownership to the 181,540 shares. Before that another transaction happened on Nov 11 ’24, when Company’s Chief Executive Officer sold 30,000 for $55.62, making the entire transaction worth $1,668,678. This insider now owns 196,540 shares in total.
CRISPR Therapeutics AG (CRSP) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around -166.03% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -17.11% during the next five years compared to 10.83% growth over the previous five years of trading.
CRISPR Therapeutics AG (NASDAQ: CRSP) Trading Performance Indicators
Here are CRISPR Therapeutics AG’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 21.64. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 16.71.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.82, a number that is poised to hit -1.19 in the next quarter and is forecasted to reach -5.04 in one year’s time.
Technical Analysis of CRISPR Therapeutics AG (CRSP)
CRISPR Therapeutics AG (NASDAQ: CRSP) saw its 5-day average volume 1.87 million, a negative change from its year-to-date volume of 1.96 million. As of the previous 9 days, the stock’s Stochastic %D was 33.75%. Additionally, its Average True Range was 2.11.
During the past 100 days, CRISPR Therapeutics AG’s (CRSP) raw stochastic average was set at 14.15%, which indicates a significant increase from 7.62% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 47.12% in the past 14 days, which was lower than the 49.46% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $43.56, while its 200-day Moving Average is $49.82. Nevertheless, the first resistance level for the watch stands at $41.18 in the near term. At $42.66, the stock is likely to face the second major resistance level. The third major resistance level sits at $43.57. If the price goes on to break the first support level at $38.79, it is likely to go to the next support level at $37.88. The third support level lies at $36.40 if the price breaches the second support level.
CRISPR Therapeutics AG (NASDAQ: CRSP) Key Stats
With a market capitalization of 3.39 billion, the company has a total of 85,353K Shares Outstanding. Currently, annual sales are 371,210 K while annual income is -153,610 K. The company’s previous quarter sales were 600 K while its latest quarter income was -85,940 K.
